Takashi Niizeki

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 130 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Serum C‐reactive protein levels predict survival in hepatocellular carcinoma

Sakae Nagaoka, Takafumi Yoshida, Junji Akiyoshi et al. · Liver International · 2007 · 101 citations

Medicine, Oncology, Cancer Immunology +8

Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis

Hajime Aino, Shuji Sumie, Takashi Niizeki et al. · Molecular and Clinical Oncology · 2014 · 84 citations · Full text

Medicine, Oncology, Hepatology +15

High expression of <scp>CD</scp>44v9 and <scp>xCT</scp> in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine

Fumitaka Wada, Hironori Koga, Jun Akiba et al. · Cancer Science · 2018 · 82 citations · Full text

Medicine, Oncology, Pharmacology +16